WallStreetZenWallStreetZen

NASDAQ: SPRO
Spero Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for SPRO

Based on 1 analyst offering 12 month price targets for Spero Therapeutics Inc.
Min Forecast
$7.00+398.22%
Avg Forecast
$7.00+398.22%
Max Forecast
$7.00+398.22%

Should I buy or sell SPRO stock?

Based on 1 analyst offering ratings for Spero Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SPRO stock forecasts and price targets.

SPRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-18

1 of 1

Forecast return on equity

Is SPRO forecast to generate an efficient return?
Company
N/A
Industry
-62.55%
Market
20.01%

Forecast return on assets

Is SPRO forecast to generate an efficient return on assets?
Company
N/A
Industry
6.28%

SPRO revenue forecast

What is SPRO's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$49.2M-52.59%
Avg 2 year Forecast
$48.0M-53.75%
SPRO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SPRO revenue growth forecast

How is SPRO forecast to perform vs Biotechnology companies and vs the US market?
Company
-31.99%
Industry
59.52%
Market
9.23%
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SPRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRO$1.41$7.00+398.22%Buy
CVM$1.51N/AN/A
AFMD$5.00$13.33+166.66%Buy
CUE$1.57$8.00+409.55%Strong Buy
LVTX$2.85$6.00+110.53%Buy

Spero Therapeutics Stock Forecast FAQ

Is Spero Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SPRO) stock is to Buy SPRO stock.

Out of 1 analyst, 0 (0%) are recommending SPRO as a Strong Buy, 1 (100%) are recommending SPRO as a Buy, 0 (0%) are recommending SPRO as a Hold, 0 (0%) are recommending SPRO as a Sell, and 0 (0%) are recommending SPRO as a Strong Sell.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

What is SPRO's revenue growth forecast for 2024-2025?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -31.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Spero Therapeutics's revenue in 2024 is $103,781,000.On average, 1 Wall Street analysts forecast SPRO's revenue for 2024 to be $2,650,361,639, with the lowest SPRO revenue forecast at $2,650,361,639, and the highest SPRO revenue forecast at $2,650,361,639.

In 2025, SPRO is forecast to generate $2,585,718,672 in revenue, with the lowest revenue forecast at $2,585,718,672 and the highest revenue forecast at $2,585,718,672.

What is SPRO's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: SPRO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 6.28%.

What is SPRO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SPRO price target, the average SPRO price target is $7.00, with the highest SPRO stock price forecast at $7.00 and the lowest SPRO stock price forecast at $7.00.

The Wall Street analyst predicted that Spero Therapeutics's share price could reach $7.00 by Mar 18, 2025. The average Spero Therapeutics stock price prediction forecasts a potential upside of 398.22% from the current SPRO share price of $1.41.

What is SPRO's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: SPRO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.